



Please distribute the attached customer letter.  
To the Laboratory Manager  
To the attention of the Healthcare center Chairman

Address  
City, Date

Our reference: FSCA#5308-2

**IMPORTANT:**

**URGENT FIELD SAFETY NOTICE**

**MYLA® V4.7 (V4.7.1) - Ref. 423270 ; V4.8 (V4.8.1 or V4.8.2) - Ref. 423434**

**Bottle unloaded before the end of incubation – potential false negative result WITH VIRTUO®**

Dear valued bioMérieux Customer,

Our records indicate that your laboratory has received one or more of the products listed below:

Reference	Product Name	Version
423434	MYLA® SOFTWARE	V4.8 ; V4.8.1 ; V4.8.2
423270	MYLA® SOFTWARE	V4.7.1
423270	MYLA® SOFTWARE	V4.7

Following one customer complaint, a MYLA® software anomaly has been confirmed that can result in a bottle maximum test time (MTT) being reset to the default MTT. The bottle may then be unloaded before the desired incubation time.

This can occur specifically when an identification of a paired bottle is made outside of MYLA® and the result is sent back to MYLA® from the Laboratory Information System (LIS).

**This issue could appear if MTT is driven by LIS requests. This issue can't appear if customer is using MTT feature directly through VIRTUO® instrument interface.**

Below is an example of the workflow that can generate this anomaly:

- Two LIS requests, one for aerobic bottle, one for anaerobic bottle are sent to MYLA® for one specimen. Both LIS requests are sent with an extension of the standard incubation time (MTT) to 14 days. By default, the incubation time is 5 days as per specified in the bottle Instructions for Use.
- One of the two bottles turns positive and is automatically unloaded from the VIRTUO® instrument (to do a subculture).

Subsidiary name (if applicable) / Nom de la filiale (si approprié)



- The identification is made outside of MYLA® and the result is sent back to MYLA® from the LIS as a request containing an offline identification result.

As a result of this anomaly, the MTT of the second bottle is updated back to the default MTT of 5 days after receiving the offline identification result. This second bottle will be then be unloaded when the incubation time reaches 5 Days (which could be immediately depending on the duration already incubated). Thus presenting the risk of a false negative result.

**For the anomaly to occur, the conditions below must be met:**

Conditions	Yes	No
You are using MYLA® (V4.7, V4.7.1, V4.8, V4.8.1 or V4.8.2) in conjunction with BCI Connect	<input type="checkbox"/>	<input type="checkbox"/>
<b>AND</b>	<input type="checkbox"/>	<input type="checkbox"/>
You are managing Blood Culture analyses on BACT/ALERT® VIRTUO® connected to MYLA®	<input type="checkbox"/>	<input type="checkbox"/>
<b>AND</b>	<input type="checkbox"/>	<input type="checkbox"/>
Your Blood Culture workflow is based on 2 or more bottles with the same specimen (same specimen/laboratory id)	<input type="checkbox"/>	<input type="checkbox"/>
<b>AND</b>	<input type="checkbox"/>	<input type="checkbox"/>
You are using the LIS capability to send Blood Culture requests containing the incubation expected duration (MTT)	<input type="checkbox"/>	<input type="checkbox"/>
<b>AND</b>	<input type="checkbox"/>	<input type="checkbox"/>
You are sending other requests than Blood Culture (Offline SU, ID,) on the same specimen than the one used for BC <i>note: this condition is applicable only if it occurs after the previous ones, chronologically speaking</i>	<input type="checkbox"/>	<input type="checkbox"/>

If one or more answers is NO, your laboratory is not at risk for this anomaly.

**Impact to customer:**

The risk for the customers/patients is to obtain a false negative result due to the bottle being unloaded before the end of scheduled incubation time.

**Required actions:**

We request you to take the following actions at this time:

- Please distribute this information to all appropriate personnel in your laboratory, retain a copy in your files, and forward this information to all parties that may use this product.
- **Please check if you meet the requested conditions for a potential issue mentioned in Table 2 above:**
  - If you answer “No” to one of these questions, you are not impacted by this anomaly. Please indicate this on the customer acknowledgement form.
  - If you answer “Yes” to all those questions, please contact bioMérieux to assist you in resolving the problem. Please indicate this on the customer acknowledgement form.

**Subsidiary name (if applicable) / Nom de la filiale (si approprié)**



An Annex (Annex 1) is available to assist customers on issue's conditions identification. In case of any doubt, do not hesitate to contact your bioMérieux representative should you need assistance with these conditions verification.



5308-2 - FSCA -  
Annex 1 - EN.pdf

- For tests previously performed using MYLA® and VIRTUO® (as detailed in Table 2), we recommend you to identify any possible false negative result that may have occurred, to analyze the related risks and to determine appropriate actions, if relevant.
- Contact your bioMérieux Field Service Engineer to apply the mandatory correction as needed.
  - o Next MYLA® version (V4.9) fixes the issue.
  - o Awaiting this version to be released, specific workaround can be applied aligned with customer workflow.
- Complete the Acknowledgement Form in Attachment A and return it to your local bioMérieux representative to confirm receipt of this notice.

bioMérieux is committed to providing our customers with the highest quality product possible. We sincerely apologize for any inconvenience that this may have caused you. If you require additional assistance or have any questions, please contact your local bioMérieux Customer Service representative.

Thank you for your continued use of bioMérieux products,

**bioMérieux, Inc.**

**Subsidiary name (if applicable) / Nom de la filiale (si approprié)**



**Attachment A: Acknowledgement Form.**

**URGENT FIELD SAFETY NOTICE**

**FSCA 5308-2 - MYLA® V4.7, V4.7.1, V4.8, V4.8.1 or V4.8.2  
Ref. 423270 ; 423434**

**Bottle unloaded before the end of incubation – potential false negative result WITH VIRTUO®**

**TO BE RETURNED TO YOUR BIO-MERIEUX CUSTOMER SERVICE AT THE FOLLOWING  
FAX NUMBER : XXXXXXXX**

Name of the laboratory:

City:

**Customer number:**

- I acknowledge receipt of the bioMérieux letter regarding “MYLA® V4.8/V4.8.1/V4.8.2 ref. 423434 and MYLA® V4.7/V4.7.1 ref. 423270 – bottle unloaded before the end of incubation - potential false negative result with VIRTUO®”
- I will implement the required actions indicated in the Urgent Field Safety Notice.

**Based on table 2 (Issue required conditions):**

- I met conditions of a potential issue (ticked box “Yes” for all questions) and I have called bioMérieux for Workaround application

**OR**

- I did not meet all conditions of a potential issue (ticked box “No” for at least one question), so I am not impacted by this issue
- Have you encountered impact on patients’ results, or reports of illness or injury related to the identified issue ?
  - Yes    No

**DATE .....**

**SIGNATURE : .....**

**Subsidiary name (if applicable) / Nom de la filiale (si approprié)**